Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.

Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TM.

Endocr Relat Cancer. 2017 Aug;24(8):393-404. doi: 10.1530/ERC-17-0107. Epub 2017 Jun 29.

PMID:
28663228
2.

Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.

Bubley GJ, Balk SP.

J Clin Oncol. 2017 Jul 1;35(19):2103-2105. doi: 10.1200/JCO.2017.72.8808. Epub 2017 Apr 17. No abstract available.

PMID:
28414609
3.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

PMID:
28212060
4.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

PMID:
28151719
5.

Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.

Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3823-3833. doi: 10.1158/1078-0432.CCR-16-2414. Epub 2017 Jan 24.

PMID:
28119368
6.

Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.

McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME.

Clin Genitourin Cancer. 2017 Aug;15(4):463-471. doi: 10.1016/j.clgc.2016.10.006. Epub 2016 Oct 27.

PMID:
27890446
7.

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin ME.

Clin Cancer Res. 2017 Feb 15;23(4):935-945. doi: 10.1158/1078-0432.CCR-16-0987. Epub 2016 Sep 28. Erratum in: Clin Cancer Res. 2017 Jul 15;23 (14 ):3970.

8.

The Molecular Taxonomy of Primary Prostate Cancer.

Cancer Genome Atlas Research Network.

Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025.

9.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22.

10.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators.

Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.

PMID:
25601341
11.

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, Lattime EC, Gulley JL, Arlen PM, Butterfield LH, Wilding G.

Eur Urol. 2015 Sep;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010. Epub 2014 Dec 18.

12.

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME.

Clin Cancer Res. 2015 Mar 15;21(6):1273-80. doi: 10.1158/1078-0432.CCR-14-1220. Epub 2014 Oct 15.

13.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW.

J Clin Oncol. 2014 Nov 20;32(33):3705-15. doi: 10.1200/JCO.2013.53.4578. Epub 2014 Oct 13.

14.

Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.

Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li W.

Mol Cancer Res. 2015 Jan;13(1):98-106. doi: 10.1158/1541-7786.MCR-14-0273. Epub 2014 Sep 4.

15.

Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.

J Clin Oncol. 2014 Jun 20;32(18):1889-94. doi: 10.1200/JCO.2013.52.4785. Epub 2014 May 12.

PMID:
24821883
16.

Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder.

Delto JC, Kacker R, Bubley G, DeWolf WC.

Clin Genitourin Cancer. 2014 Feb;12(1):e35-6. doi: 10.1016/j.clgc.2013.08.005. Epub 2013 Oct 26. No abstract available.

PMID:
24169496
17.

Dramatic and prolonged PSA response after retreatment with a PSA vaccine.

Rojan A, Funches R, Regan MM, Gulley JL, Bubley GJ.

Clin Genitourin Cancer. 2013 Sep;11(3):362-4. doi: 10.1016/j.clgc.2013.01.003. Epub 2013 Jun 20. No abstract available.

PMID:
23791437
18.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

19.

Reply: To PMID 23490517.

Holupka E, Bubley GJ.

Urology. 2013 Jun;81(6):1289-90. doi: 10.1016/j.urology.2012.12.057. Epub 2013 Mar 13. No abstract available.

PMID:
23490531
20.

Accuracy of endorectal magnetic resonance/transrectal ultrasound fusion for detection of prostate cancer during brachytherapy.

Bubley GJ, Bloch BN, Vazquez C, Genega E, Holupka E, Rofsky N, Kaplan I.

Urology. 2013 Jun;81(6):1284-9. doi: 10.1016/j.urology.2012.12.051. Epub 2013 Mar 13.

PMID:
23490527

Supplemental Content

Loading ...
Support Center